Necroptosis and Reactive Oxygen Species-associated cell death pathways

Necroptosis is a regulated form of necrotic cell death that is independent of caspases and characterized by cell swelling and plasma membrane rupture. It is primarily mediated by the RIPK1-RIPK3-MLKL signaling axis, often triggered by TNF-alpha or toll-like receptor activation [PMID: 22265413]. Reactive oxygen species (ROS) frequently accumulate during this process, contributing to mitochondrial dysfunction and oxidative damage that exacerbates the necrotic phenotype [PMID: 19524513]. This pathway plays a critical role in various pathologies, including inflammatory diseases, neurodegeneration, and ischemia-reperfusion injury, making its components attractive therapeutic targets [PMID: 28559550]. Drugs targeting this pathway, such as RIPK1 or RIPK3 inhibitors, aim to prevent the pro-inflammatory release of cellular contents associated with necroptotic cell death [PMID: 30279484]. The interplay between necroptosis and ROS is complex, as ROS can both trigger the pathway and be produced as a consequence of RIPK3 activation. Therapeutic intervention in this pathway is being explored for conditions like myocardial infarction and Alzheimer's disease, where preventing cell loss and the subsequent inflammatory response is crucial. However, challenges remain regarding the specificity of inhibitors and the potential for cells to switch to alternative death modes like apoptosis when necroptosis is blocked.

Other names

Programmed necrosisNecroptotic signaling pathwayRIPK1/RIPK3/MLKL pathwayROS-mediated necroptosis

Inhibition of RIPK1 or RIPK3 kinase activity, or prevention of MLKL oligomerization and membrane translocation, to block the execution of regulated necrosis and the subsequent release of pro-inflammatory damage-associated molecular patterns (DAMPs).